Dimethyl Fumarate for Pediatric-Onset Multiple Sclerosis: A Systematic Review

IF 3.2 3区医学 Q2 CLINICAL NEUROLOGY

Pediatric neurology Pub Date : 2025-03-20 DOI:10.1016/j.pediatrneurol.2025.03.008

Masoud Etemadifar MD , Hasan Kaveyee MD , Yasin Ebne-Ali-Heydari MD , Parto Zohrabi MD , Pantea Miralaei MD , Nahad Sedaghat MD , Amir Mohammad Jozaie MD , Mehri Salari MD , Aryana Ramezani MD

{"title":"Dimethyl Fumarate for Pediatric-Onset Multiple Sclerosis: A Systematic Review","authors":"Masoud Etemadifar MD , Hasan Kaveyee MD , Yasin Ebne-Ali-Heydari MD , Parto Zohrabi MD , Pantea Miralaei MD , Nahad Sedaghat MD , Amir Mohammad Jozaie MD , Mehri Salari MD , Aryana Ramezani MD","doi":"10.1016/j.pediatrneurol.2025.03.008","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Dimethyl fumarate (DMF) is an oral disease-modifying therapy (DMT) being used for adult patients with multiple sclerosis (MS) with acceptable safety and efficacy profile. The use of DMF for pediatric-onset multiple sclerosis (POMS) is being considered especially for patients who prefer a self-administered oral DMT. To systematically review the experience with DMF in POMS regarding the safety and efficacy profile.</div></div><div><h3>Methods</h3><div>This systematic review was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Three different databases were searched (PubMed, Scopus, and Web of Science) to find relevant articles until the end of May 15, 2024. Data were screened and extracted by two independent authors.</div></div><div><h3>Results</h3><div>From 344 studies, six studies with 316 patients were included in the systematic review. DMF had an acceptable effect on reducing relapses and magnetic resonance imaging activity. Gastrointestinal discomfort and facial flushing were the most reported adverse events related to the use of DMF in patients with POMS.</div></div><div><h3>Conclusions</h3><div>DMF could be considered for patients with POMS both as first-line and switching therapy. Despite a recent tendency toward high-efficacy DMTs for POMS, DMF remains a good option for certain cases.</div></div>","PeriodicalId":19956,"journal":{"name":"Pediatric neurology","volume":"167 ","pages":"Pages 52-59"},"PeriodicalIF":3.2000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric neurology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0887899425000712","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Dimethyl fumarate (DMF) is an oral disease-modifying therapy (DMT) being used for adult patients with multiple sclerosis (MS) with acceptable safety and efficacy profile. The use of DMF for pediatric-onset multiple sclerosis (POMS) is being considered especially for patients who prefer a self-administered oral DMT. To systematically review the experience with DMF in POMS regarding the safety and efficacy profile.

Methods

This systematic review was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Three different databases were searched (PubMed, Scopus, and Web of Science) to find relevant articles until the end of May 15, 2024. Data were screened and extracted by two independent authors.

Results

From 344 studies, six studies with 316 patients were included in the systematic review. DMF had an acceptable effect on reducing relapses and magnetic resonance imaging activity. Gastrointestinal discomfort and facial flushing were the most reported adverse events related to the use of DMF in patients with POMS.

Conclusions

DMF could be considered for patients with POMS both as first-line and switching therapy. Despite a recent tendency toward high-efficacy DMTs for POMS, DMF remains a good option for certain cases.

查看原文本刊更多论文

富马酸二甲酯治疗儿科多发性硬化症：系统综述

富马酸二甲酯（DMF）是一种用于多发性硬化症（MS）成人患者的口腔疾病改善疗法（DMT），具有可接受的安全性和有效性。使用DMF治疗儿科起病多发性硬化症（POMS）正在考虑，特别是那些喜欢自行口服DMT的患者。系统回顾DMF在POMS中的安全性和有效性。方法根据系统评价和荟萃分析指南的首选报告项目进行系统评价。检索了三个不同的数据库（PubMed， Scopus和Web of Science）以查找相关文章，直到2024年5月15日结束。数据由两位独立作者筛选和提取。结果从344项研究中，有6项研究共纳入了316例患者。DMF在减少复发和磁共振成像活性方面具有可接受的效果。胃肠道不适和面部潮红是与POMS患者使用DMF相关的最多报道的不良事件。结论sdmf可作为POMS患者的一线治疗和转换治疗。尽管最近倾向于采用高效的dmt治疗POMS，但DMF仍然是某些病例的良好选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric neurology 医学-临床神经学

CiteScore

4.80

自引率

2.60%

发文量

176

审稿时长

78 days

期刊介绍： Pediatric Neurology publishes timely peer-reviewed clinical and research articles covering all aspects of the developing nervous system. Pediatric Neurology features up-to-the-minute publication of the latest advances in the diagnosis, management, and treatment of pediatric neurologic disorders. The journal''s editor, E. Steve Roach, in conjunction with the team of Associate Editors, heads an internationally recognized editorial board, ensuring the most authoritative and extensive coverage of the field. Among the topics covered are: epilepsy, mitochondrial diseases, congenital malformations, chromosomopathies, peripheral neuropathies, perinatal and childhood stroke, cerebral palsy, as well as other diseases affecting the developing nervous system.